Micafungin Hikma (Micafungin)

Micafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, which is required to build β‑(1,3)‑D‑glucan, an essential structural component of the fungal cell wall. Inhibiting this pathway weakens the wall, causing osmotic instability and ultimately leading to fungal cell death while sparing human cells.

The appropriate dose of Micafungin Hikma is determined by the prescribing healthcare professional based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for micafungin in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient before initiating therapy.

To order Micafungin Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis. Echinocandins like micafungin are often preferred for invasive Candida infections, especially in patients with azole resistance or intolerance, because they have a different mechanism and a lower risk of drug‑drug interactions with many azoles.

Micafungin Hikma should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Maintaining the cold‑chain ensures stability and potency of the intravenous solution.

Micafungin Hikma is given as an intravenous infusion. The infusion is administered by a healthcare professional, typically over a period of 30‑60 minutes, depending on the prescribed regimen and patient tolerance. The exact rate and duration are determined by the prescribing clinician.

Serious adverse events include hepatic failure, severe allergic reactions such as anaphylaxis, and rare infusion‑related reactions that may cause hypotension or respiratory distress. Patients should be monitored for signs of liver toxicity, hypersensitivity, and any acute infusion symptoms throughout treatment.

Micafungin Hikma should be avoided in individuals with a known hypersensitivity to micafungin or any other echinocandin. Caution is also advised for patients with severe hepatic impairment, and it should be used only after careful risk assessment in pregnant or breastfeeding women.